Quanterix Announces New Agreement With Janssen Sciences Ireland UC, To Advance Blood Based Alzheimer's Disease Detection
Portfolio Pulse from Benzinga Newsdesk
Quanterix Corporation (NASDAQ:QTRX) has signed a license agreement with Janssen Sciences Ireland UC, a Johnson & Johnson (J&J) Company, to receive worldwide, non-exclusive rights to J&J's p-Tau 217 antibodies and assay designs for potential use in clinical research and diagnostic products. This strengthens Quanterix's position in the Alzheimer's Disease biomarker field. Quanterix will also launch a Laboratory Developed Test based on the J&J p-Tau 217 antibodies and assay, marking a significant milestone in advancing Alzheimer's Disease diagnosis and treatment.
October 24, 2023 | 2:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's subsidiary, Janssen, has signed a license agreement with Quanterix, which could potentially increase J&J's influence in the Alzheimer's Disease research and diagnostics field.
The agreement allows Quanterix to use J&J's p-Tau 217 antibodies and assay designs, which could potentially increase J&J's influence and recognition in the Alzheimer's Disease research and diagnostics field.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Quanterix's new agreement with Janssen could strengthen its position in the Alzheimer's Disease biomarker field and potentially increase its market share.
The agreement provides Quanterix with access to J&J's p-Tau 217 antibodies and assay designs, which could enhance its product offerings and potentially increase its market share in the Alzheimer's Disease research and diagnostics field.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100